News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
487,131 Results
Type
Article (8023)
Company Profile (141)
Press Release (478967)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166743)
Career Advice (304)
Deals (25741)
Drug Delivery (7)
Drug Development (52875)
Employer Resources (14)
FDA (9760)
Job Trends (8573)
News (238198)
Policy (17899)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (8)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (493)
Accelerated approval (27)
ADA (18)
Adcomms (1)
Allergies (100)
Alliances (33157)
ALS (115)
Alzheimer's disease (990)
Antibody-drug conjugate (ADC) (304)
Approvals (10444)
Artificial intelligence (348)
ASCO (161)
Autoimmune disease (231)
Automation (32)
Bankruptcy (263)
Belgium (3)
Best Places to Work (6957)
BIO (36)
Biologics (23)
BIOSECURE Act (1)
Biosimilars (122)
BioSpace Insights (17)
Biotechnology (89)
Bispecific (7)
Bladder cancer (141)
Brain cancer (34)
Breast cancer (528)
Cancer (3877)
Cardiovascular disease (233)
Career advice (245)
Career pathing (1)
CAR-T (183)
CDC (1)
CDMO (25)
Celiac Disease (3)
Cell therapy (500)
Cervical cancer (36)
Clinical research (48267)
Collaboration (1325)
Commercialization (17)
Compensation (1595)
Complete response letters (35)
COVID-19 (764)
CRISPR (66)
C-suite (834)
Cystic fibrosis (88)
Data (6131)
Denatured (4)
Depression (108)
Dermatology (89)
Diabetes (373)
Diagnostics (4238)
Digital health (40)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (167)
Drug pricing (7)
Drug shortages (3)
Duchenne muscular dystrophy (172)
Earnings (73807)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (88417)
Executive appointments (725)
Eye disease (3)
FDA (12600)
Fibrodysplasia Ossificans Progressiva (11)
Fragile X (1)
Friedreich's ataxia (19)
Frontotemporal dementia (25)
Funding (983)
Gene editing (129)
Generative AI (11)
Gene therapy (343)
GLP-1 (304)
Government (948)
Grass and pollen (2)
Guidances (281)
Healthcare (9373)
Hematology (95)
HIV (55)
Huntington's disease (24)
Idiopathic pulmonary fibrosis (3)
IgA nephropathy (72)
Immunology and inflammation (111)
Immuno-oncology (64)
Indications (172)
Infectious disease (961)
Inflammatory bowel disease (134)
Inflation Reduction Act (4)
Influenza (87)
Intellectual property (269)
Interviews (41)
IPO (12392)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (17)
Kidney disease (62)
Labor market (1)
Layoffs (59)
Legal (5195)
Licensing (30)
Liver cancer (46)
Longevity (21)
Lung cancer (561)
Lung diease (8)
Lymphoma (264)
Machine learning (29)
Management (3)
Manufacturing (599)
Marketing (12)
MASH (120)
Medical affairs (2)
Medical device (8702)
Medtech (8871)
Mergers & acquisitions (14437)
Metabolic disorders (752)
mRNA (70)
Multiple sclerosis (110)
Multispecific (1)
NASH (4)
Netherlands (1)
Neurodegenerative disease (235)
Neuropsychiatric disorders (40)
Neuroscience (1911)
Neurotech (1)
NextGen: Class of 2026 (3150)
Non-profit (843)
Obesity (236)
Opinion (10)
Ovarian cancer (174)
Pain (183)
Pancreatic cancer (219)
Parkinson's disease (214)
Partnered (12)
Patents (519)
Patient advocacy (1)
Patient recruitment (541)
Patient selection (27)
Peanut (33)
People (41449)
Peptides (11)
Pharmaceutical (30)
Pharmacy benefit managers (10)
Phase 1 (15578)
Phase 2 (21558)
Phase 3 (14551)
Pipeline (8101)
Policy (18)
Postmarket research (1570)
Preclinical (6574)
Press Release (34)
Prostate cancer (199)
Psychedelics (10)
Radiopharmaceuticals (201)
Rare diseases (612)
Real estate (3024)
Recruiting (6)
Regenerative medicine (9)
Regulatory (15103)
Reports (23)
Research institute (589)
Resumes & cover letters (45)
Rett syndrome (45)
RNA editing (8)
RSV (48)
Schizophrenia (108)
Series A (172)
Series B (125)
Service/supplier (5)
Sickle cell disease (64)
Spinal muscular atrophy (92)
Sponsored (5)
Startups (2020)
Stomach cancer (3)
Substance use disorders (16)
Supply chain (52)
Vaccines (341)
Venture capital (17)
Weight loss (77)
Wet AMD (1)
Women's health (93)
Date
Today (87)
Last 7 days (338)
Last 30 days (1416)
Last 365 days (19169)
2026 (14756)
2025 (19254)
2024 (22992)
2023 (26540)
2022 (34588)
2021 (37167)
2020 (33468)
2019 (23256)
2018 (17468)
2017 (18766)
2016 (17917)
2015 (24263)
2014 (21679)
2013 (18135)
2012 (20221)
2011 (20440)
2010 (20332)
Location
Africa (230)
Alabama (80)
Alaska (2)
Arizona (315)
Arkansas (12)
Asia (18007)
Australia (2114)
California (12655)
Canada (3318)
China (560)
Colorado (514)
Connecticut (439)
Delaware (219)
Europe (24749)
Florida (1906)
Georgia (400)
Hawaii (3)
Idaho (46)
Illinois (752)
India (57)
Indiana (328)
Iowa (17)
Japan (443)
Kansas (104)
Kentucky (33)
Louisiana (27)
Maine (27)
Maryland (1252)
Massachusetts (8278)
Michigan (319)
Minnesota (586)
Mississippi (4)
Missouri (83)
Montana (20)
Nebraska (11)
Nevada (127)
New Hampshire (60)
New Jersey (2782)
New Mexico (12)
New York (2969)
North Carolina (1342)
North Dakota (4)
Northern California (6393)
Ohio (300)
Oklahoma (14)
Oregon (16)
Pennsylvania (2354)
Puerto Rico (24)
Rhode Island (30)
South America (407)
South Carolina (79)
South Dakota (1)
Southern California (5268)
Tennessee (128)
Texas (2080)
United States (41017)
Utah (384)
Vermont (1)
Virginia (161)
Washington D.C. (39)
Washington State (976)
West Virginia (1)
Wisconsin (81)
Wyoming (1)
487,131 Results for "systimmune inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
SystImmune Receives FDA Clearance of IND Application for Bispecific Antibody SI-B037
September 22, 2026
·
2 min read
Press Releases
SystImmune, Inc. to Present New Global Data on Iza-bren (izalontamab brengitecan) in EGFR-mutated Non-Small Cell Lung Cancer at WCLC Congress 2026
September 13, 2026
·
4 min read
Press Releases
SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
July 17, 2026
·
5 min read
Press Releases
SystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer
August 5, 2026
·
3 min read
Press Releases
SystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in China
June 23, 2026
·
5 min read
Press Releases
SystImmune Reports Phase 1 Data for BL-M14D1 Demonstrating Promising Activity in Small-Cell Lung Cancer at ASCO
June 1, 2026
·
4 min read
Press Releases
SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Extensive Stage Small Cell Lung Cancer at ELCC 2026
March 19, 2026
·
3 min read
Press Releases
SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration
October 13, 2025
·
5 min read
Press Releases
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
February 26, 2026
·
7 min read
Business
SystImmune, Inc. Announces Transition of Chief Medical Officer
SystImmune, Inc., a pioneering clinical-stage biopharmaceutical company focused on developing novel therapeutic bi-specific, multi-specific antibodies, and antibody-drug conjugates for the treatment of cancer, announced the appointment of Dr. Jonathan Cheng as Chief Medical Officer.
May 23, 2024
·
2 min read
1 of 48,714
Next
